Rxi Pharmaceuticals (RXII) 1.20 $RXII
RXi Pharmaceuticals enters into exclusive global licensing agreement for Samcyprone
M2 - Fri Feb 06, 5:25AM CST
Biotechnology company RXi Pharmaceuticals (NasdaqCM:RXII) announced Thursday that it has completed its exclusive global license agreement for the therapeutic use of Samcyprone from Hapten Pharmaceuticals.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Announces Closing of the Exclusive Global Licensing Agreement to Samcyprone(TM) with Hapten Pharmaceuticals
PR Newswire - Thu Feb 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone(TM) with Hapten Pharmaceuticals, LLC.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications
PR Newswire - Tue Feb 03, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for the delivery of double stranded siRNAs (21 to 23 nucleotides in length) across the blood-retina barrier (e.g. topical or systemic delivery) for the treatment of wet age-related macular degeneration or diabetic retinopathy. The patent, part of RXi's acquired OPKO estate, is scheduled to expire in 2023.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's Chief Development Officer, Dr. Pamela Pavco, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 9:00 a.m. EST in New York City. Dr. Pavco will provide an update on the Company's Dermatology and Ophthalmology Franchises.
RXII: 1.20 (-0.03)
Insider Trading Alert - RXII, MA And SWN Traded By Insiders
at The Street - Mon Jan 26, 9:19AM CST
Stocks with insider trader activity include RXII, MA and SWN
RXII: 1.20 (-0.03), SWN: 27.36 (+0.51), MA: 87.14 (-0.38)
Update: After A Massive Sell-Off, The CEO Is Buying RXi Pharmaceuticals Stock
Christopher F. Davis - at Seeking Alpha - Tue Jan 20, 7:27PM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase(TM)
PR Newswire - Mon Jan 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7th Annual Biotech Showcase(TM) 2015 on Monday, January 12, 2015 at 9:30 a.m. PST. Dr. Cauwenbergh will provide an update on the Company's Dermatology and Ophthalmology Franchises. He will also discuss business development opportunities with RXi's broad delivery technology platform as well as the Company's robust intellectual property portfolio.
RXII: 1.20 (-0.03)
Update: Addressing RXi Pharmaceuticals' Letter To Shareholders
Christopher F. Davis - at Seeking Alpha - Wed Dec 24, 11:28AM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals: Stock Appears On Sale Following 2 Big Announcements
Christopher F. Davis - at Seeking Alpha - Tue Dec 23, 12:25PM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Issues Open Letter to Shareholders
PR Newswire - Mon Dec 22, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today issued the following open letter to shareholders from President & CEO, Geert Cauwenbergh, Dr. Med. Sc.
RXII: 1.20 (-0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST
RBY: 1.11 (unch), FATE: 5.00 (-0.07), IMDZ: 25.34 (+1.20), RXII: 1.20 (-0.03), GLMD: 6.80 (+0.03), TBIO: 2.91 (+0.01), SIM: 8.29 (+0.24), PHMD: 1.68 (+0.04), IMGN: 7.19 (unch), PETX: 16.52 (-0.10), NQ: 3.95 (-0.03), OTIC: 31.14 (+0.13), VHC: 5.53 (+0.09), FINL: 23.51 (-0.32), BBLU: 1.26 (+0.09), TRXC: 2.86 (-0.11), BAS: 7.28 (+0.62), ENRJ: 2.81 (+0.06), TNK: 5.50 (+0.10)
RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound
PR Newswire - Fri Dec 19, 6:05AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, LLC for the therapeutic use of Samcyprone(TM). Samcyprone(TM) is a proprietary gel formulation of diphenylcyclopropenone (DPCP), an immunomodulating agent that works by initiating a T-cell response. Although DPCP is not a registered drug, it is used successfully by dermatologists as a topical immunomodulator to treat dermatological diseases. Samcyprone(TM) is expected to demonstrate an improved safety and use profile over DPCP as currently applied. A Phase 2a trial to evaluate the efficacy and safety of Samcyprone(TM) for the treatment of viral warts has been completed and Phase 2a trials for the treatment of cutaneous metastases of various cancers including melanoma and for the treatment of alopecia areata are underway.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
PR Newswire - Wed Dec 17, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced completion of enrollment in its first Phase 2a study, RXI-109-1301. The preliminary results from the 3-month observations confirmed the 1-month findings that were reported in September of this year:
RXII: 1.20 (-0.03)
Update: RXi Pharmaceuticals Reports Q3 Earnings; My Thoughts On Its Cash Position
Christopher F. Davis - at Seeking Alpha - Thu Nov 13, 4:40PM CST
RXII: 1.20 (-0.03)
RXi Pharma net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:35AM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals beats by $0.05, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:19AM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2014
PR Newswire - Thu Nov 13, 6:10AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the quarter ended September 30, 2014, and provided a business update.
RXII: 1.20 (-0.03)
Market Maker Surveillance Report. CTC, DRL, CAMP, RBCN, RXII, SOPW, Winning Stocks With Lowest Price Friction For Tuesday, October 7th 2014
M2 - Wed Oct 08, 4:25AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4746 companies with "abnormal" market making, 1204 companies with positive Friction Factors and 3932 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Canadian Tire Corp Ltd (NYSE:CTC), Diadem Resources Ltd (NYSE
RL), CalAmp Corp (NASDAQ:CAMP), Rubicon Technology Inc (NASDAQ:RBCN), RXi Pharmaceuticals Corp (NASDAQ:RXII), Solar Power Inc (OTC:SOPW). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
RXII: 1.20 (-0.03), CAMP: 18.55 (+0.07), CTC: 0.68 (-0.09), DRL: 2.31 (+0.10), RBCN: 4.53 (-0.13)
RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109
PR Newswire - Tue Oct 07, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may be effective in suppressing recurrence of hypertrophic scars at the 3-month time point. Patients will continue to be monitored through 9 months to evaluate if this outcome persists over time.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
PR Newswire - Mon Sep 29, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 10:00 a.m. PST. Dr. Cauwenbergh will discuss the development of RXI--109, a self-delivering RNAi compound designed to reduce dermal scarring. He will also provide an overview of the development opportunities on the Company's discovery programs targeting collagenase and tyrosinase, as well as business development opportunities with RXi's broad delivery technology platform.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals enters into exclusive global licensing agreement for Samcyprone
M2 - Fri Feb 06, 5:25AM CST
Biotechnology company RXi Pharmaceuticals (NasdaqCM:RXII) announced Thursday that it has completed its exclusive global license agreement for the therapeutic use of Samcyprone from Hapten Pharmaceuticals.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Announces Closing of the Exclusive Global Licensing Agreement to Samcyprone(TM) with Hapten Pharmaceuticals
PR Newswire - Thu Feb 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone(TM) with Hapten Pharmaceuticals, LLC.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications
PR Newswire - Tue Feb 03, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for the delivery of double stranded siRNAs (21 to 23 nucleotides in length) across the blood-retina barrier (e.g. topical or systemic delivery) for the treatment of wet age-related macular degeneration or diabetic retinopathy. The patent, part of RXi's acquired OPKO estate, is scheduled to expire in 2023.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's Chief Development Officer, Dr. Pamela Pavco, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 9:00 a.m. EST in New York City. Dr. Pavco will provide an update on the Company's Dermatology and Ophthalmology Franchises.
RXII: 1.20 (-0.03)
Insider Trading Alert - RXII, MA And SWN Traded By Insiders
at The Street - Mon Jan 26, 9:19AM CST
Stocks with insider trader activity include RXII, MA and SWN
RXII: 1.20 (-0.03), SWN: 27.36 (+0.51), MA: 87.14 (-0.38)
Update: After A Massive Sell-Off, The CEO Is Buying RXi Pharmaceuticals Stock
Christopher F. Davis - at Seeking Alpha - Tue Jan 20, 7:27PM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase(TM)
PR Newswire - Mon Jan 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7th Annual Biotech Showcase(TM) 2015 on Monday, January 12, 2015 at 9:30 a.m. PST. Dr. Cauwenbergh will provide an update on the Company's Dermatology and Ophthalmology Franchises. He will also discuss business development opportunities with RXi's broad delivery technology platform as well as the Company's robust intellectual property portfolio.
RXII: 1.20 (-0.03)
Update: Addressing RXi Pharmaceuticals' Letter To Shareholders
Christopher F. Davis - at Seeking Alpha - Wed Dec 24, 11:28AM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals: Stock Appears On Sale Following 2 Big Announcements
Christopher F. Davis - at Seeking Alpha - Tue Dec 23, 12:25PM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Issues Open Letter to Shareholders
PR Newswire - Mon Dec 22, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today issued the following open letter to shareholders from President & CEO, Geert Cauwenbergh, Dr. Med. Sc.
RXII: 1.20 (-0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST
RBY: 1.11 (unch), FATE: 5.00 (-0.07), IMDZ: 25.34 (+1.20), RXII: 1.20 (-0.03), GLMD: 6.80 (+0.03), TBIO: 2.91 (+0.01), SIM: 8.29 (+0.24), PHMD: 1.68 (+0.04), IMGN: 7.19 (unch), PETX: 16.52 (-0.10), NQ: 3.95 (-0.03), OTIC: 31.14 (+0.13), VHC: 5.53 (+0.09), FINL: 23.51 (-0.32), BBLU: 1.26 (+0.09), TRXC: 2.86 (-0.11), BAS: 7.28 (+0.62), ENRJ: 2.81 (+0.06), TNK: 5.50 (+0.10)
RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound
PR Newswire - Fri Dec 19, 6:05AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, LLC for the therapeutic use of Samcyprone(TM). Samcyprone(TM) is a proprietary gel formulation of diphenylcyclopropenone (DPCP), an immunomodulating agent that works by initiating a T-cell response. Although DPCP is not a registered drug, it is used successfully by dermatologists as a topical immunomodulator to treat dermatological diseases. Samcyprone(TM) is expected to demonstrate an improved safety and use profile over DPCP as currently applied. A Phase 2a trial to evaluate the efficacy and safety of Samcyprone(TM) for the treatment of viral warts has been completed and Phase 2a trials for the treatment of cutaneous metastases of various cancers including melanoma and for the treatment of alopecia areata are underway.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
PR Newswire - Wed Dec 17, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced completion of enrollment in its first Phase 2a study, RXI-109-1301. The preliminary results from the 3-month observations confirmed the 1-month findings that were reported in September of this year:
RXII: 1.20 (-0.03)
Update: RXi Pharmaceuticals Reports Q3 Earnings; My Thoughts On Its Cash Position
Christopher F. Davis - at Seeking Alpha - Thu Nov 13, 4:40PM CST
RXII: 1.20 (-0.03)
RXi Pharma net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:35AM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals beats by $0.05, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:19AM CST
RXII: 1.20 (-0.03)
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2014
PR Newswire - Thu Nov 13, 6:10AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the quarter ended September 30, 2014, and provided a business update.
RXII: 1.20 (-0.03)
Market Maker Surveillance Report. CTC, DRL, CAMP, RBCN, RXII, SOPW, Winning Stocks With Lowest Price Friction For Tuesday, October 7th 2014
M2 - Wed Oct 08, 4:25AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4746 companies with "abnormal" market making, 1204 companies with positive Friction Factors and 3932 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Canadian Tire Corp Ltd (NYSE:CTC), Diadem Resources Ltd (NYSE
RL), CalAmp Corp (NASDAQ:CAMP), Rubicon Technology Inc (NASDAQ:RBCN), RXi Pharmaceuticals Corp (NASDAQ:RXII), Solar Power Inc (OTC:SOPW). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . RXII: 1.20 (-0.03), CAMP: 18.55 (+0.07), CTC: 0.68 (-0.09), DRL: 2.31 (+0.10), RBCN: 4.53 (-0.13)
RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109
PR Newswire - Tue Oct 07, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may be effective in suppressing recurrence of hypertrophic scars at the 3-month time point. Patients will continue to be monitored through 9 months to evaluate if this outcome persists over time.
RXII: 1.20 (-0.03)
RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
PR Newswire - Mon Sep 29, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 10:00 a.m. PST. Dr. Cauwenbergh will discuss the development of RXI--109, a self-delivering RNAi compound designed to reduce dermal scarring. He will also provide an overview of the development opportunities on the Company's discovery programs targeting collagenase and tyrosinase, as well as business development opportunities with RXi's broad delivery technology platform.
RXII: 1.20 (-0.03)
